Methyl 1-carbamoylpiperidine-4-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Methyl 1-carbamoylpiperidine-4-carboxylate
• 化学式: C₈H₁₄N₂O₃
• mdl: MFCD07313891
• 分子量: 186.21
• InChiKey: DYOXWIVVARYOFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH<br/>[FR] MODULATEURS SÉLECTIFS DES RÉCEPTEURS DE LA SPHINGOSINE-1-PHOSPHATE ET TRAITEMENT COMBINÉ LES UTILISANT
  申请人：RECEPTOS INC

  公开号：WO2015066515A1

  公开（公告）日：2015-05-07

  Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided, including compounds which modulate subtype 1 of the S1P receptor, and methods of their therapeutic and/or prophylactic use in combination with at least one other medicament adapted for treatement of a malcondition for which activation of S1P1 is medically indicated, such as multiple sclerosis.

  提供了选择性调节神经酰胺1磷酸受体的化合物，包括调节S1P受体亚型1的化合物，以及它们在与至少一种其他适用于治疗激活S1P1的药物联合使用的治疗和/或预防用途的方法，例如多发性硬化症。
• [EN] PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS<br/>[FR] PYRIDINOYLPIPERIDINES UTILISEES COMME AGONISTES DE 5-HT1F
  申请人：LILLY CO ELI

  公开号：WO2003084949A1

  公开（公告）日：2003-10-16

  The present invention relates to compounds of formula I:or pharmaceutically acceptable acid addition salts thereof, where;R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II II;R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl;R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

  本发明涉及以下公式的化合物：或其药学上可接受的酸盐，其中; R1是C1-C6烷基，取代的C1-C6烷基，C3-C7环烷基，取代的C3-C7环烷基，C3-C7环烷基-C1-C3烷基，取代的C3-C7环烷基-C1-C3烷基，苯基，取代的苯基，杂环，或取代的杂环; R2是氢，C1-C3烷基，C3-C6环烷基-C1-C3烷基，或公式II的基团 II; R3是氢或C1-C3烷基; R4是氢，卤素，或C1-C3烷基; R5是氢或C1-C3烷基; R6是氢或C1-C6烷基; n是从1到6的整数（包括1和6）。本发明的化合物可用于激活5-HT1F受体，抑制神经蛋白外渗，并用于哺乳动物偏头痛的治疗或预防。本发明还涉及一种合成公式I化合物合成中间体的方法。
• Pyridinoylpiperidines as 5-ht1f agonists
  申请人：Cohen Philip Michael

  公开号：US20050222206A1

  公开（公告）日：2005-10-06

  The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II R 3 is hydrogen or C 1 -C 3 alkyl; R 4 is hydrogen, halo, or C 1 -C 3 alkyl; R 5 is hydrogen or C 1 -C 3 alkyl; R 6 is hydrogen or C 1 -C 6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5 -HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

  本发明涉及式I的化合物或其药学上可接受的酸加成盐，其中；R1是C1-C6烷基，取代的C1-C6烷基，C3-C7环烷基，取代的C3-C7环烷基，C3-C7环烷基-C1-C3烷基，取代的C3-C7环烷基-C1-C3烷基，苯基，取代的苯基，杂环或取代的杂环；R2是氢，C1-C3烷基，C3-C6环烷基-C1-C3烷基或IIR3的基团；R3是氢或C1-C3烷基；R4是氢，卤素或C1-C3烷基；R5是氢或C1-C3烷基；R6是氢或C1-C6烷基；n为1到6的整数，包括1和6。 本发明的化合物对于激活5-HT1F受体，抑制神经蛋白外渗以及治疗或预防哺乳动物偏头痛具有用处。本发明还涉及一种用于合成式I化合物中间体的合成过程。
• Pyridinoylpiperidines as 5-HT1F agonists
  申请人：Cohen Michael Philip

  公开号：US20080300407A1

  公开（公告）日：2008-12-04

  The invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II; R 3 is hydrogen or C 1 -C 3 alkyl; R 4 is hydrogen, halo, or C 1 -C 3 alkyl; R 5 is hydrogen or C 1 -C 3 alkyl; R 6 is hydrogen or C 1 -C 6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

  本发明涉及I式化合物： 或其药学上可接受的酸加合物，其中： R1是C1-C6烷基，取代的C1-C6烷基，C3-C7环烷基，取代的C3-C7环烷基，C3-C7环烷基-C1-C3烷基，取代的C3-C7环烷基-C1-C3烷基，苯基，取代的苯基，杂环或取代的杂环； R2是氢，C1-C3烷基，C3-C6环烷基-C1-C3烷基或II式的基团； R3是氢或C1-C3烷基； R4是氢，卤素或C1-C3烷基； R5是氢或C1-C3烷基； R6是氢或C1-C6烷基； n是1到6的整数。 本发明的化合物对于激活5-HT1F受体，抑制神经元蛋白外渗以及用于哺乳动物偏头痛的治疗或预防是有用的。本发明还涉及一种在化合物I的合成中间体合成的过程。
• Pyridinoylpiperidines As 5-HT1F Agonists
  申请人：Cohen Michael P.

  公开号：US20120329820A1

  公开（公告）日：2012-12-27

  The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II R 3 is hydrogen or C 1 -C 3 alkyl; R 4 is hydrogen, halo, or C 1 -C 3 alkyl; R 5 is hydrogen or C 1 -C 3 alkyl; R 6 is hydrogen or C 1 -C 6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

  本发明涉及公式I的化合物或其药学上可接受的酸加成盐，其中：R1是C1-C6烷基，取代的C1-C6烷基，C3-C7环烷基，取代的C3-C7环烷基，C3-C7环烷基-C1-C3烷基，取代的C3-C7环烷基-C1-C3烷基，苯基，取代的苯基，杂环或取代的杂环；R2是氢，C1-C3烷基，C3-C6环烷基-C1-C3烷基，或公式II的基团；R3是氢或C1-C3烷基；R4是氢，卤素或C1-C3烷基；R5是氢或C1-C3烷基；R6是氢或C1-C6烷基；n是从1到6的整数。本发明的化合物可用于激活5-HT1F受体，抑制神经元蛋白外渗，并用于哺乳动物偏头痛的治疗或预防。本发明还涉及一种合成公式I化合物中间体的合成过程。